Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus:oralvs.parenteral; home vs. hospital

International Journal of Antimicrobial Agents

Volumn 34, Issue SUPPL. 1, 2009, Pages

  Esposito, Silvano ^a   Leone, Sebastiano ^a,b   Petta, Ester ^a   Noviello, Silvana ^a   Ianniello, Filomena ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

Meticillin resistant Staphylococcus aureus; Oral administration; Outpatient parenteral therapy; Parenteral administration; Skin and soft tissue infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; FUSIDIC ACID; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERIOSTASIS; BLOOD TOXICITY; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFECTION PREVENTION; INFECTIOUS PNEUMONIA; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OPTIC NERVE DISEASE; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE INFECTION; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 67649197354     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70547-3     Document Type: Article

References (47)

1. Jevons M.P. 'Celbenin-resistant' staphylococci. Br Med J 1 (1961) 124-125
2. Diekema D.J., BootsMiller B.J., Vaughn T.E., Woolson R.F., Yankey J.W., Ernst E.J., et al. Antimicrobial resistance trends and outbreak frequency in United States Hospitals. Clin Infect Dis 38 (2004) 78-85
3. Stryjewski M.E., and Chambers H.F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5 (2008) S368-S377
4. Engemann J.J., Carmeli Y., Cosgrove S.E., Fowler V.G., Bronstein M.Z., Trivette S.L., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
5. Moellering Jr. R.C. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46 (2008) 1032-1037
6. Klein E., Smith D.L., and Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13 (2007) 1840-1846
7. Frazee B.W., Lynn J., Charlebois E.D., Lambert L., Lowery D., and Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 45 (2005) 311-320
8. Szumowski J.D., Cohen D.E., Kanaya F., and Mayer K.H. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51 (2007) 423-428
9. Pallin D.J., Egan D.J., Pelletier A.J., Espinola J.A., Hooper D.C., and Camargo Jr. C.A. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 51 (2008) 291-298
10. Esposito S., Noviello S., and Leone S. Skin and soft tissue infections: current therapeutic options [in Italian]. Infez Med 16 (2008) 65-73
11. DiNubile M.J., and Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 53 Suppl 2 (2004) 37-50
12. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A.D., and Volturo G.A. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 52 Suppl 1 (2003) 13-17
13. Hyun D.Y., Mason E.O., Forbes A., and Kaplan S.L. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 28 (2009) 57-59
14. Stevens D.L., Ma Y., Salmi D.B., McIndoo E., Wallace R.J., and Bryant A.E. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195 (2007) 202-211
15. Dumitrescu O., Boisset S., Badiou C., Bes M., Benito Y., Reverdy M.E., et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 51 (2007) 1515-1519
16. Martínez-Aguilar G., Hammerman W.A., Mason Jr. E.O., and Kaplan S.L. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22 (2003) 593-598
17. Drekonja D.M., Traynor L.M., DeCarolis D.D., Crossley K.B., and Johnson J.R. Treatment of non-life-threatening methicillin-resistant Staphylococcus aureus infections with alternative antimicrobial agents: a 2-year retrospective review. Diagn Microbiol Infect Dis 63 (2009) 201-207
18. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34 (2002) 482-492
19. Siberry G.K., Tekle T., Carroll K., and Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37 (2003) 1257-1260
20. Cenizal M.J., Skiest D., Luber S., Bedimo R., Davis P., Fox P., et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 2628-2630
21. Enoch DA, Karas JA, Aliyu SH. Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by meticillin-resistant Staphylococcus aureus (MRSA) in the UK. Int J Antimicrob Agents. Epub 2008 Dec 18.
22. Minuth J.N., Holmes T.M., and Musher D.M. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother 6 (1974) 411-414
23. Ruhe J.J., Monson T., Bradsher R.W., and Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 40 (2005) 1429-1434
24. Ruhe J.J., and Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 3298-3303
25. Schmitz F.J., Krey A., Sadurski R., Verhoef J., Milatovic D., and Fluit A.C. Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates. J Antimicrob Chemother 47 (2001) 239-240
26. Nathwani D., Morgan M., Masterton R.G., Dryden M., Cookson B.D., French G., et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61 (2008) 976-994
27. Cox R.A., Mallaghan C., Conquest C., and King J. Epidemic methicillin-resistant Staphylococcus aureus: controlling the spread outside hospital. J Hosp Infect 29 (1995) 107-119
28. Sorrell T.C., Packham D.R., Shanker S., Foldes M., and Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97 (1982) 344-350
29. Bozdogan B., and Appelbaum P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23 (2004) 113-119
30. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall S.E., Todd W.M., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillindicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 44 (2000) 3408-3413
31. Wilcox M., Nathwani D., and Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 53 (2004) 335-344
32. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C., and Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
33. Falagas M.E., Siempos I.I., and Vardakas K.Z. Linezolid versus glycopeptide or betalactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8 (2008) 53-66
34. Karchmer A.W., and Bayer A.S. Methicillin-resistant Staphylococcus aureus:an evolving clinical challenge. Clin Infect Dis 46 Suppl 5 (2008) S342-S343
35. Gould I.M. The problem with glycopeptides. Int J Antimicrob Agents 30 (2007) 1-3
36. Wang G., Hindler J.F., Ward K.W., and Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 (2006) 3883-3886
37. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
38. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., and Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
39. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46 (2008) 193-200
40. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 25 (2005) 185-192
41. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E., Tigecycline 300 cSSSI Study Group, and Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
42. Steenbergen J.N., Alder J., Thorne G.M., and Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55 (2005) 283-288
43. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skinstructure infections. Clin Infect Dis 38 (2004) 1673-1681
44. Esposito S., Noviello S., Leone S., Tice A., Seibold G., Nathwani D., et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 24 (2004) 473-478
45. Tice A.D., Rehm S.J., Dalovisio J.R., Bradley J.S., Martinelli L.P., Graham D.R., et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 38 (2004) 1651-1672
46. Corwin P., Toop L., McGeoch G., Than M., Wynn-Thomas S., Wells J.E., et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 330 (2005) 129-134
47. Martone W.J., Lindfield K.C., and Katz D.E. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 62 (2008) 1183-1187